Clene Inc. Files 8-K Report

TL;DR

Clene filed a routine 8-K, no major news.

AI Summary

Clene Inc. filed an 8-K on September 25, 2025, reporting on other events and financial statements. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing indicates Clene Inc. is meeting its reporting obligations with the SEC, but it does not disclose any new material information that would immediately impact investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not contain any disclosed material events or financial information that would indicate increased risk.

Key Players & Entities

• Clene Inc. (company) — Registrant
• September 25, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 6550 South Millrock Drive, Suite G50 (address) — Principal executive offices
• Salt Lake City, Utah (location) — Principal executive offices location

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value CLNN The Nasdaq Capital M
• $230.00 — rtieth of one share of Common Stock for $230.00 per share CLNNW The Nasdaq Capital

Filing Documents

• clnn20250923_8k.htm (8-K) — 31KB
• ex_863758.htm (EX-99.1) — 2KB
• ex_863757.htm (EX-99.2) — 22KB
• slide1.jpg (GRAPHIC) — 469KB
• 0001437749-25-029846.txt ( ) — 856KB
• clnn-20250925.xsd (EX-101.SCH) — 4KB
• clnn-20250925_def.xml (EX-101.DEF) — 14KB
• clnn-20250925_lab.xml (EX-101.LAB) — 18KB
• clnn-20250925_pre.xml (EX-101.PRE) — 14KB
• clnn20250923_8k_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. In connection with the press release discussed under Item 8.01 in this Current Report on Form 8-K (the "Current Report"), on September 25, 2025, Clene Inc. (the "Company") presented new clinical data at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis ("ECTRIMS 2025") demonstrating CNM-Au8 improves brain energy metabolism in multiple sclerosis patients. A copy of the poster is furnished as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The information furnished in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in any such filings, except as shall be expressly set forth by specific reference in such a filing.

01 Other Events

Item 8.01 Other Events. On September 25, 2025, the Company issued a press release announcing a presentation of new clinical data at ECTRIMS 2025 meeting demonstrating CNM-Au8 improves brain energy metabolism in multiple sclerosis patients. A copy of the press release is filed as Exhibit 99.2 to this Current Report and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 REPAIR-MS Poster. 99.2 Press release, dated September 25, 2025, announcing Clene presents new clinical data at ECTRIMS 2025 meeting demonstrating CNM-Au8 improves brain energy metabolism in multiple sclerosis patients. 104 Cover Page Interactive Data File (formatted as Inline XBRL). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CLENE INC. Date: September 25, 2025 By: /s/ Robert Etherington Robert Etherington President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR